[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635061":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":15,"locations":23,"responsibleParty":41,"collaborators":7,"id":43,"slug":7,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":7,"maxAge":7,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Akeso","INDUSTRY",null,[9,13],{"name":10,"affiliation":11,"role":12},"Jiafu Ji, MD","Peking University Cancer Hospital & Institute","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":11,"role":12},"Lin Shen, MD",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Zhifang Yao，MD","CONTACT","86-0760-89873999","clinicaltrials@akesobio.com",{"name":10,"role":18,"phone":7,"phoneExt":7,"email":22},"jijiafu@hsc.pku.edu.cn",[24],{"facility":25,"status":26,"city":27,"state":7,"zip":7,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Peking University Cancer Hospital","RECRUITING","Beijing","China","CN",{"type":31,"coordinates":32},"Point",[33,34],116.39723,39.9075,{"lat":34,"lon":33},[37,39],{"name":38,"role":18,"phone":7,"phoneExt":7,"email":22},"Jiafu Ji, MD, Principal Investigator",{"name":40,"role":18,"phone":7,"phoneExt":7,"email":7},"Lin Shen, MD, Principal Investigator",{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100635061",false,"NCT07547787","A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)","An Extension Study for Collecting Long-term Follow-up Data of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)","Inclusion Criteria:\n\n1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.\n2. Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.\n3. Agree to proceed with the extended follow-up procedures.\n4. This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.\n\nExclusion Criteria:\n\n* None","ALL",{"count":51,"type":52},610,"ESTIMATED","5 Years","OBSERVATIONAL","This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1\u002FCTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.",[57],"Locally Advanced Unresectable or Metastatic Gastric Cancer","2026-04-17",{"date":60,"type":61},"2026-04-23","ACTUAL",{"date":63,"type":61},"2024-12-26",{"date":65,"type":52},"2040-12-31",{"name":5,"class":6},1]